Characterization and optimization of clove oil-loaded nanomicelles for the possible topical use of bacterial infection-led atopic dermatitis

Background: Atopic dermatitis is an abnormal skin condition that impacts a significant number of people in the US, with an estimated 9.6 million children and 16.5 million adults being affected by it. The study aimed to characterize and optimize clove oil-based nanomicelles for the possible topical use of bacterial infection-led atopic dermatitis. Clove oil-loaded nanomicelles were produced and carefully analyzed for vesicle diameter, polydispersity index (PDI), zeta potential, morphological attributes, entrapment efficiency, in vitro release, stability, dermatokinetic parameters, 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging behavior and antibacterial activity. Different models, such as Korsmeyer, Higuchi, first order, and zero order were employed to evaluate the in vitro release from the formulations. Results: The average size of the clove oil nanomicelles was found to be 100.15 nm with a PDI of 0.2104; they were observed to be darker against a light background. The evaluated mean zeta size was 121.3 nm, the zeta potential was − 15.31 mV. The inhibitory concentration 50 (IC₅₀) of the formulation was 61.32 ± 0.98 μg/mL; clove oil was 73.56 ± 1.63 μg/mL, against ascorbic acid was 54.51 ± 0.79 μg/mL. Among the four models tested for in vitro release kinetics, the Korsmeyer Peppas model was followed by the nanomicelles formulation. Clove oil nanomicelles generated a higher concentration of 148.68 w/v on the skin epidermis within 1.5 h, whereas the conventional formulation exhibited 55.287 w/v. Moreover, clove oil nanomicelles generated a higher concentration of 125.84 µg/mL on the skin's dermis within 2 h, whereas the conventional formulation produced 68.263 µg/mL. The nanomicelles also inhibited bacterial growth within a 24-h period. Conclusions: The study presents initial evidence regarding the potency of clove oil-based nanomicelles and their enhanced efficiency on the skin. Thus, the prepared formulation can further be studied and incorporated for the possible use against bacterial infection-led atopic dermatitis. Graphical abstract: [Figure not available: see fulltext.]